Availability of immunohistochemistry in the diagnosis of follicular variant of papillary thyroid carcinoma

Korean Journal of Pathology

Volumn 44, Issue 1, 2010, Pages 48-55

  Jeong, Ji Yun ^a   Jang, Jung Sik ^a   Sohn, Yoon Kyung ^a   Jung, Jin Hyang ^b   Chun, Yi Kyeong ^c   Park, Ji Young ^a  

^a Departments of Pathology   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Catholic Kwandong University   (South Korea)

Author keywords

Carcinoma; Follicular variant; Immunohistochemistry; Papillary; Thyroid gland

Indexed keywords

EID: 77955044526     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2010.44.1.48     Document Type: Article

References (29)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. WHO classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, 2004.
2. Rosai J, Carcangiu M, DeLellis RA. Atlas of Tumor Pathology. Tumors of the thyroid gland. Washington, DC: Armed Forces Institute of Pathology, 1992.
3. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003; 97: 1181-5.
4. Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002; 117: 16-8.
5. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004; 28: 1336-40.
6. Renshaw AA, Gould EW. Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002; 117: 19-21.
7. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005; 18: 48-57.
8. Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of galectin-3, HB- ME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007; 22: 621-8.
9. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008; 3: 5.
10. Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004; 9: 305-28.
11. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin- 3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005; 47: 391-401.
12. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002; 126: 710-3.
13. Park MI, Kang DY. Usefulness of galectin-3, cytokeratin 19, p53, and Ki-67 for the differential diagnosis of thyroid tumors. Korean J Pathol 2006; 40: 86-92.
14. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992; 23: 107-16.
15. Miettinen M, Kärkkäinen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch 1996; 429: 213-9.
16. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001; 3: 650-7.
17. Prag S, Lepekhin EA, Kolkova K, et al. NCAM regulates cell motility. J Cell Sci 2002; 115: 283-92.
18. Fogar P, Basso D, Pasquali C, et al. Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias. Anticancer Res 1997; 17: 1227-30.
19. Zeromski J, Dworacki G, Jenek J, et al. Protein and mRNA expression of CD56/N-CAM on follicular epithelial cells of the human thyroid. Int J Immunopathol Pharmacol 1999; 12: 23-30.
20. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113: 1661-70.
21. Preto A, Reis-Filho JS, Ricardo S, Soares P. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract 2002; 198: 449-54.
22. Kim YW, Do IG, Park YK. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract 2006; 202: 759-65.
23. Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol 2003; 34: 764-9.
24. Burstein DE, Nagi C, Wang BY, Unger P. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto's thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol 2004; 35: 465-73.
25. Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol 2002; 117: 143-50.
26. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy. Otolaryngol Head Neck Surg 2005; 132: 840-4.
27. Yuksel O, Kurukahvecioglu O, Ege B, et al. The relation between pure papillary and follicular variant in papillary thyroid carcinoma. Endocr Regul 2008; 42: 29-33.
28. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169: 2233-8.
29. Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 2007; 212: 411-9.